Ovid Therapeutics Inc OVID

Morningstar Rating
$2.15 −0.11 (4.87%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OVID is trading at a LOCK|<h!hZ premium.
Price
$2.15
Fair Value
LOCK|m#@Zy^
Uncertainty
LOCK|!P ZwG?s
1-Star Price
LOCK|?P@GXy
5-Star Price
LOCK|^hr<$%
Economic Moat
LOCK|pD@
Capital Allocation
—

News

Trading Information

Previous Close Price
$2.26
Day Range
$2.11–2.30
52-Week Range
$1.18–3.11
Bid/Ask
$2.11 / $2.65
Shares Outstanding
195.30M
Market Cap
$419.89M
Volume/Avg
1M / 2M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
165.07
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
23

Valuation

Metric
OVID
Price/Earnings (Normalized)
—
Price/Book Value
1.89
Price/Sales
165.07
Price/Cash Flow
—
Price/Earnings
OVID

Financial Strength

Metric
OVID
Quick Ratio
11.75
Current Ratio
12.39
Interest Coverage
—
Quick Ratio
OVID

Profitability

Metric
OVID
Return on Assets (Normalized)
−33.89%
Return on Equity (Normalized)
−39.75%
Return on Invested Capital (Normalized)
−35.98%
Return on Assets
OVID

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$MgT?!hLOCK|^<%F$127B
Moderna Inc
MRNA
LOCK|&fPnW#>LOCK|!M>$87B
Regeneron Pharmaceuticals Inc
REGN
LOCK|c&Wk@hLOCK|wTb^T$81B
argenx SE ADR
ARGX
LOCK|TF@J!VCLOCK|y&d$51B
BeOne Medicines Ltd ADR
ONC
LOCK|<zQ%h>rLOCK|s>?$44B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|vchbpwLOCK|$>cV$31B
Royalty Pharma PLC Class A
RPRX
LOCK|bQBhDpdLOCK|?>c#$27B
Incyte Corp
INCY
LOCK|?ZXF<f>LOCK|tw$23B
BioNTech SE ADR
BNTX
LOCK|$^^k$$LOCK|Rlw$22B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|YV#@rkLOCK|@hz$14B

Sponsor Center